Scholar Rock Holding Corporation’s SRRK share price has dipped by 5.79%, which has investors questioning if this is right ...

Biotech stock Scholar Rock (NASDAQ: SRRK) was popular among investors on Wednesday after a positive new analyst note on the ...

Pundit Allison Bratzel is quite bullish on its leading drug candidate. Scholar Rock targets relatively uncommon disorders that might lack effective treatments. Its current lead drug candidate ...

Scholar Rock Holding Corp (NASDAQ:SRRK) is on track to launch apitegromab, a muscle-targeted therapy for SMA, in the US in 2025, with plans to expand to the EU in 2026. The SAPPHIRE study showed ...

On Wednesday, Piper Sandler reiterated an Overweight rating and a $42.00 price target on Scholar Rock stock (NASDAQ:SRRK), as analysts anticipate the company’s upcoming Q2 2025 proof-of-concept ...

Regulatory Milestones: BLA for apitegromab submitted in the US in January; MAA submission in the EU on track for March. Scholar Rock Holding Corp (NASDAQ:SRRK) is on track to launch apitegromab, a ...

Shares in Scholar Rock have gone into overdrive after the biotech reported positive phase 3 results with apitegromab in patients with spinal muscular atrophy (SMA), setting up regulatory filings ...

U.S. Army Lt. John W. Gunnison, then working on a survey of the Great Lakes, wrote a letter to his Mormon friend, Albert ...

A legal scholar discusses the Trump administration's embrace of the theory that the president alone has authority over the ...

1 Day SRRK 2.78% DJIA 1.07% S&P Mid Cap 400 1.34% Health Care/Life Sciences -1.43% ...